Biologics MDPI

This systematic review by Dr. Rehak and colleagues reframes PRP as an immune-regenerative therapy, emphasizing the need for well-designed, standardized clinical trials to fully understand its potential.

🔎Check out their whole paper at: https://brnw.ch/21x242Y

✨ Paper Recommendation

Dr. Seker-Yilmaz and colleagues explore the rapidly evolving field of fetal therapy. Advances in medicine are transforming how we approach severe congenital and genetic disorders, starting treatment even before birth.

🔗 Full review paper is available at: https://brnw.ch/21x242C

Dr. Moutinho and colleagues fro the University of Lisbon demonstrated the potential of engineered sdAbs as cost-effective, scalable biologics, not only for COVID-19 but also for future emerging infectious diseases.

📖Read their full article at:

A Rabbit-Derived Single-Domain Antibody Fused to the Streptococcus zooepidemicus Zag Protein Engineered for SARS-CoV-2 Neutralization and Extended Half-Life Background/Objectives: The continuous emergence of immune-evasive SARS-CoV-2 variants underscores the need for adaptable and accessible therapeutics that complement vaccination. Single-domain antibodies (sdAbs) offer advantages in size, stability, and production costs compared to conventional monocl...

⭐Targeting oncogenic protein–protein interactions (PPIs) has long been a major challenge in cancer research. This new study by Prakash et al. introduces an innovative computational approach to address this problem. At the core of this work is DesignForge, a pipeline that integrates advanced tools such as AlphaFold2 and ProteinMPNN to design novel miniprotein binders targeting difficult oncogenic interfaces.

🔗Access the whole paper at:

De Novo Protein Design Enables Targeting of Intractable Oncogenic Protein–Protein Interfaces Background/Objectives: Protein–protein interactions (PPIs) involving oncogenic drivers remain among the most intractable targets in cancer biology due to their dynamic conformations and limited accessibility to conventional small molecules. Although antibodies and inhibitors have achieved clinical...

Dr. Dwijayanti et al. explored in this study how natural compounds can help restore gut balance and reduce inflammation.

These results highlight beetroot’s potential as a natural dietary strategy for managing gut inflammation and microbiome-related disorders.

🔎Check out the whole paper at:

Beetroot Extract Ameliorates DSS-Induced Colitis in Mice via Gut Microbiota Modulation Background: Dextran sodium sulfate (DSS)-induced colitis serves as a preclinical model for studying gut dysbiosis and inflammation relevant to inflammatory bowel disease (IBD) and its long-term complication of colorectal cancer (CRC). Beetroot (Beta vulgaris L.) extract, rich in betalains, polypheno...

A recent study, “A Single-Center Review of Infusion-Associated Reactions in Patients with CLN2 Disease Receiving Cerliponase Alfa” by Dr. Whiteley and colleagues from Great Ormond Street Hospital, provides valuable real-world evidence on the safety and management of enzyme replacement therapy in pediatric patients.

🔗Check out the whole article online:

A Single-Center Review of Infusion-Associated Reactions in Patients with CLN2 Disease Receiving Cerliponase Alfa Background: Cerliponase alfa is an intracerebroventricular (ICV) enzyme replacement therapy (ERT) and the only approved treatment for neuronal ceroid lipofuscinosis type 2 (CLN2) disease. While generally well tolerated, infusion-associated reactions (IARs), including hypersensitivity events and anap...

🎊 We’re excited to announce that we will be exhibiting at the 2026 Annual Congress of the European Association for Cancer Research in Budapest, Hungary!

💬 Stop by booth #101 to discuss with our representatives about open access publishing opportunities and get insights into how to share and promote your research.

📆 8-11 June 2026
📍 Budapest, Hungary
🔗More details: https://brnw.ch/21x1SR3

📣Join us at the AACR Annual Meeting 2026!

📢 Stop by our booth to connect, exchange ideas, and dive into the Open Access publishing world. Our representatives are looking forward to discussing with you!

🎊We’re excited to announce that our team will be attending the AACR Annual Meeting 2026, taking place from 17–22 April 2026 in San Diego.

📍 You can find us at booth #3645, where our delegates will be happy to connect, discuss our journals, and answer any questions you may have.

Whether you're a researcher, clinician, or industry professional, we’d love to meet you in person, exchange ideas, and explore opportunities for collaboration.

🔗 https://www.mdpi.com/about/announcements/14550

AACR Annual Meeting 2026, 17–22 April 2026, San Diego, CA, USA The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other healthcare professionals, survivors,...

🎊Our first Issue of the year is out now (Volume 6, Issue 1)!

On the cover: "Complement Inhibitors and the Risk of (Breakthrough) Infections—Critical Analysis and Preventive Strategies" by Dr. Halacova and colleagues.

This issue brings together cutting-edge research and insights into the development and application of biologic therapies, highlighting progress across the biomedical and life sciences fields.

👉 Explore the full issue: https://brnw.ch/21x1cpD

Dr. Abushahba wrote about an innovative strategy to tackle human brucellosis, a major global One Health challenge.

While these results are based on in silico analyses, they provide a strong theoretical foundation for next-generation vaccine development against brucellosis.

🔍Read the whole article: https://brnw.ch/21x15Os